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ABSTRACT
Objectives: The specific purpose of this study was the assessment of A5935G, G5949A, G6081A, G6267A mutations in 
MT-CO1 and T9540C in MT-CO3, and alterations detected during the analysis of MT-CO gene fragments in subject and control 
groups. A secondary aim was to assess the relationship between MT-CO1 and MT-CO3 gene alterations and endometrial 
cancer incidence and evaluation of the prognostic value of MT-CO1 and MT-CO3 gene alterations.
Material and methods: In this study, we investigated A5935G, G5949A, G6081A, G6267A mutations in MT-CO1 and T9540C 
in MT-CO3, and alterations detected during the analysis of MT-CO gene fragments in formalin-fixed, paraffin-embedded 
endometrial and benign endometrial hyperplasia of a cohort of 125 subjects. 
Results: The T9540C mutation in MT-CO3 was detected in one patient from the subject group. None of the remaining muta-
tions were detected. The research showed that the presence of alterations in MT-CO1 and MT-CO3 typical of other types of 
cancer is not a risk factor for endometrial cancer.
Analysis of MT-CO1 and MT-CO3 gene fragments revealed 10 alterations (6 and 4 respectively). The alterations detected 
were identified in 10% of the tested group and 8% of the control group. 
Conclusions: The research showed that the presence of alterations in MT-CO1 (A5935G, G5949A, G6081A, G6267A) typical 
of other types of cancer is not a risk factor for endometrial cancer. Three new alterations detected in this study (A6052G, 
A9545G, G9575A) were described for the first time. 
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INTRODUCTION
In recent years, there has been a rise in the number 
of reported mtDNA mutations predisposing to neoplasm 
growth. There are few studies concerning MT-CO genes 
mutations on endometrial cancer development. Thus, the 
present study is an attempt to complete the knowledge 
concerning the meaning of mtDNA disorders in endometrial 
cancer development.
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We would like to focus on A5935G, G5949A, G6081A, 
G6267A mutations in MT-CO1 and T9540C in MT-CO3 pres-
ence and other variants of MT-CO1 and MT-CO3 gene frag-
ments in the study population. The mutations selected for 
this research occur in prostate, breast, pancreatic cancer, 
colorectal cancer as well as ulcerative colitis [1, 2].
Alterations of MT-CO can lead to dysfunction of mi-
tochondrial respiratory chain complex IV, which leads to 
changes in cellular metabolism, resulting in modifications 
to the cell’s susceptibility to cancerous transformation [3–5].
A5935G, G5949A, G6081A, G6267A are nonsynonymous 
mutations which stem from transition (A-G or G-A) and 
change the amino acid in protein product of MT-CO1.
The A5935G mutation exchanges asparagine for ser-
ine at position 11 in cytochrome c oxidase’s first subunit, 
resulting in protein function impairment. Substitution of 
an asparagine radical for a serine radical prevents the for-
mation of multiple hydric bonds, which may disrupt protein 
tertiary structure. In addition, the alteration can destabilize 
transmembrane protein (conduit D) structure, which serves 
as a pathway for proton transfer in oxygen reduction [1, 6, 7].
Another G5949A mutation, detected in prostate cancer, 
triggers premature formation of STOP codon in MT-CO1, 
which results in a shorter polypeptide length of 15 amino 
acids, instead of 513 amino acids. The shorter polypeptide 
product is highly unstable and quickly breaks down. In 
effect, this mutation decreases COX1 and COX2 levels. The 
unstable protein structure and its decreased concentration 
impairs the assembly process of oxidative phosphorylation 
IV subunit [1, 7, 8].
The G6081A mutation introduces alanine radical instead 
of threonine into the 60th position on cytochrome c oxidase. 
In most Eukaryotes, 60th position of polypeptide contains 
amino acids with a small molecular weight such as alanine 
or glycine. A replacement of alanine with threonine with its 
branched lateral chain in the 60th position and close proxim-
ity to heme group iron stabilizer histidine can disrupt protein 
helix structure. Polypeptide secondary structure dysfunction 
can affect electron transfer via α heme [7, 9, 10].
The 6267G>A change prompts the replacement of ala-
nine radical with threonine at 122th locus of the polypeptide. 
Similarly to A5935G and G6081A mutations, alanine radical 
in this locus is highly evolutionarily preserved. According 
to the authors, cells with G6267A mutation have restricted 
growth on culture medium without glucose. It can suggest 
respiratory chain failure due to this mutation [2, 7].
The T9540C mutation is a T=>C transition, character-
istic of oxidative stress damage [11]. This mutation causes 
a change in mRNA codon from UUA to CUA, which does 
not, however, lead to a change of amino acids in the protein 
chain. It is therefore a silent mutation [12].
MATERIAL AND METHODS
Material for the trial included:
 Ū formalin-fixed, paraffin-embedded (FFPE) endometrial 
cancer (adenocarcinoma endometrioides) samples col-
lected during abdominal hysterectomy and stored 
at Clinical Pathomorphology Department in “Polish 
Mother’s Memorial Hospital” Research Institute in Lodz. 
Tested samples were taken from 100 European women 
operated on for endometrial cancer of varying stages 
according to the FIGO cancer staging system and malig-
nancy grading in the Department of Gynecology ICZMP 
in Lodz from 2007 to 2014 (subject group);
 Ū formalin-fixed, paraffin-embedded (FFPE) histopatho-
logical specimens of benign endometrial hyperplasia 
stored at Clinical Pathomorphology Department. The 
samples were collected from 25 patients diagnosed with 
abnormal vaginal bleeding who underwent dilation and 
curettage (D & C) at the Department of Gynecology from 
2011 to 2012 (control group).
Ethical aspect
The study was approved by the local ethic committee 
of „Polish Mother’s Memorial Hospital” Research Institute 
(ethical agreement 3/2011).
DNA isolation
Genomic and mitochondrial DNA were extracted from 
formalin-fixed, paraffin-embedded (FFPE) endometrial can-
cer and benign endometrial hyperplasia samples by using 
the QIAamp DNA FFPE Tissue Kit (Qiagen, Germany) in accord-
ance with the manufacturer’s protocol (purified DNA is free 
of proteins, nucleases, and other impurities). 
The concentration (A260) and purity (A260/A280 ra-
tio) of isolated DNA were determined by using a PicoDrop 
— spectrophotometer (Picodrop Limited, United Kingdom). 
The extracted pure DNA was used in amplification reactions 
or stored at −20°C.
Polymerase chain reaction amplification
The purified DNA was used as a template for PCR am-
plification. The reaction mixture in 20 μL volume contained 
50 ng of DNA, 1UTaq DNA polymerase (Promega, USA), 
1.5 mM MgCl2, 0.25 mM each of dATP, dCTP, dGTP, and dTTP, 
and 0.5µM of the primers.
Amplification was performed with a thermal cycler, Gene- 
Amp PCR System 9700 (Applied Biosystems, USA).
The following COX1 and COX3 — specific sets of primers 
were used:
COX1
For: 5´-GAAAATCACCTCGGAGCTGG-3´
Rev: 5´-GATGGTTAGGTCTACGGAGG-3
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COX3 
For: 5´-GGCCTTCGATACGGGATAAT-3´
Rev: 5´-ATGGTGAGCTCAGGTGATTG-3´
Thermal cycling conditions for PCR reactions included 
an initial denaturation step at 95°C for 5 minutes followed 
by 30 cycles of a denaturation step at 95°C for 30 seconds, 
a primer annealing step at 60°C for 30 seconds, an exten-
sion step at 72°C for 30 seconds, and a final step at 72°C for 
7 minutes. 
Microchip electrophoresis of DNA fragments
The PCR amplification products were separated and 
analyzed on the automated microchip electrophoresis sys-
tem MCE-202 MultiNa (Shimadzu, Japan) using the DNA- 
-1000 kit according to the manufacturer’s protocol. A SYBR 
Gold fluorescent dye for DNA staining (Invitrogen, USA) and 
PhiX174 DNA/Hae III Markers (Promega, USA) were used to 
determine the size of the PCR products.
Sequencing
Amplification products were purified using MiniElute 
PCR Purification Kit (Qiagen, Germany). The sequencing 
reactions were run using a Big Dye® Terminator v1.1 Cycle 
Sequencing Kit (Applied Biosystems, USA) on the GeneAmp 
PCR System 9700 using standard sequencing protocols. Se-
quence analysis was performed by using the same primers 
as previously used in preamplification step.
The PCR products were purified to eliminate unincorpo-
rated primers and dNTPs using BigDye XTerminator Purifi-
cation Kit and then subjected to separation by the 3130xl 
GeneGenetic Analyzer (Applied Biosystems).
The DNA sequences were analyzed using DNA Baser 
Sequence Assembler.
Statistical analysis
STATISTICA 10.0 (StatSoft, Inc., USA) and Excel MS Office 
2013 (Microsoft Corporation, USA) software was used in 
the course of the research to process and analyze the data. 
RESULTS
The T9540C mutation in MT-CO3 was detected in one 
patient from the subject group.
None of the remaining mutations (A5935G, G5949A, 
G6081A, G6267A into MT-CO1) were detected in either pa-
tient group.
Analysis of MT-CO1 and MT-CO3 gene fragments re-
vealed 8 alterations (5 and 3 respectively). The alterations 
detected in 9% of the study group and 8% of the control 
group. The most common alterations included: A6047G 
with an incidence of 2/100 (2%) in the study group and 
1/25 (4%) in the control group and T5999C with an incidence 
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of 2/100 (2%) in the study group and 1/25 (4%). T6152C, 
G9477A mutations were also detected in the study group, 
each with an incidence of 2/100 (2%).
The remaining variants G5913A, G9575A, A9545G oc-
curred in 1% (1/100) of the study group while A6052G was 
found in 4% (1/25) of the control group.
As the above data demonstrates, only 2 MT-CO gene 
variants were detected in both the study and control group. 
Given their low incidence testing for these mutations seems 
to be unwarranted.
In the study group MT-CO1 and MT-CO3 gene variants 
were detected, whereas in the control group only alterations 
in MT-CO1 were observed.
Table 1 shows a summary of MT-CO1 and MT-CO3 genes 
mutations including medical history data from patients in 
the study and control groups.
Due to the rarity of the aforesaid alterations statistical 
analysis could not be performed as it would be unreliable.
Among the detected mutations are those observed in 
prostate cancer, pancreatic cancer, glioblastoma multiforme, 
hydatidiform mole, ovarian and thyroid cancers, head and 
neck cancers (Table 2). The remaining 3 alterations were 
described for the first time in this study (Table 3).
Three of the detected variants are transitions (A-G or 
G-A) leading to amino acid change in the protein product 
of MT-CO1 and MT-CO3. The effect of the amino acid change 
on polypeptide structure and function was analyzed based 
on UniProt database [19].
The G5913A mutation substitutes asparagine radical for 
aspartate into the 4th locus of COX1 subunit. Amino acids 
presented in the 4th locus are different for Eukaryote spe-
cies. As the data in the chart implies, the sequence contain-
ing the mutation is not evolutionarily preserved. Therefore 
it seems safe to assume that the amino acid change does 
not affect polypeptide properties.
The A6052G mutation, which causes substitution of 
asparagine with serine in the 50th locus of cytochrome c 
oxidase’s first subunit, is highly evolutionarily modified. 
Poor evolutionary variability of a given sequence may sug-
gest that amino acid substitution does not alter protein 
structure or function. 
Also the G9477A mutation causing the substitution 
of valine with isoleucine at locus 91 does not change 
the phenotype. One of the human variants of polypep-
tide first subunit of cytochrome c oxidase is the oc-
curence of isoleucine at locus 91. Isoleucine located at 
locus 91 occurs in 17.5% of the European and 6.7% of 
the African population [19]. The remaining MT-CO1 and 
MT-CO3 gene variants detected in this study do not cause 
any amino acid change.
Table 2. Detected variants in MT-CO1 and MT-CO3 in study population observed in other neoplasms
References [13, 14] [15] [13, 14] [1, 16] [17, 18]
Type of cancer
Glioblastoma 
multiforme, 
pancreatic cancer
Head and neck 
squamous cell 
carcinoma
Glioblastoma 
multiforme, 
pancreatic cancer
Prostate cancer, 
hydatidiform mole
Thyroid and 
ovarian cancers
Amino acid change Leu 48 Leu Val 83 Val Ala 32 Ala Asp 4 Asn Val 91 Ile
Altered codon sense 
mtDNA strand CTG GTC GCC AAC ATT
Codon sense 
mtDNA strand CTA GTT GCT GAC GTT
Gene name MT-CO1 MT-CO1 MT-CO1 MT-CO1 MT-CO3
Substitution A-G T-C T-C G-A G-A
Nucleotide position 
number 6047 6152 5999 5913 9477
A — adenine, C — cytosine, G — guanine, T — thymine, Leu — leucine, Val — valine, Ala — alanine, Asp — asparagine, Asn — aspartate, Ile — isoleucine
Table 3. Variants of MT-CO1 and MT-CO3 identified in the study population but absent from the available literature
Nucleotide position number Substitution Gene name Codon sense mtDNA strand
Modified codon sense 
mtDNA strand Amino acid change
6052 A-G MT-CO1 AAC AGC Asn 50 Ser
9545 A-G MT-CO3 GGA GGG Gly 113 Gly
9575 G-A MT-CO3 CCG CCA Pro 123 Pro
Leu — leucine, Asn — aspartate, Gly — glycine, Pro — prolin
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DISCUSSION
In recent years, there has been a rise in the number of re-
ported congenital and somatic mutations as well as mtDNA 
polymorphisms predisposing to neoplasm growth. Among 
the mutations tested in the subject population the T9540C 
mutation in MT-CO3 was detected in one of the patients 
diagnosed with endometrial cancer. Due to the mutation’s 
sporadic occurrence, 1/100 patients, the case is statistically 
irrelevant and does not qualify for further statistical analysis. 
The T9540C reported in breast cancer is a germline mu-
tation, i.e. one present in both cancerous and healthy cells 
of the same individual. Germline mutations are transmitted 
from one generation to the next [20]. Likewise, in case of 
ovarian cancer, investigators determined the T9540C vari-
ant to be a germline mutation based on tumor and healthy 
cell samples taken from sons of mothers diagnosed with 
ovarian cancer [21]. The T9540C mutation also occurs in 
ulcerative colitis, chronic inflammatory disease predisposing 
to colorectal cancer [22].
Analysis of MT-CO1 and MT-CO3 gene fragments for other 
changes revealed: variants in MT-CO1 (A6047G, T6152C, 
T5999C, G5913A, A6052G) and in MT-CO3 (G9477A, A9545G, 
G9575A).
Among the detected mutations are those observed 
in other neoplasms: prostate cancer and hydatidiform 
mole (G5913A) [1, 16], pancreatic tumor and glioblastoma 
multiforme (A6047G, T5999C) [13, 14], ovarian and thy-
roid cancers (G9477A) [17, 18], head and neck squamous 
cell carcinoma (T6152C) [15]. The remaining 3 alterations 
(A6052G, A9545G, G9575A) were described in this study 
for the first time.
The G5913A mutation desribed by Petros at al. [1] is 
a transition (G>A) which causes substitution of aspartate 
with asparagine at 4th locus of COX1 product. The locus 
where amino acid substitution occurred is highly evolution-
arily modified. It is therefore improbable that the changed 
amino acid affects the polypeptide’s phenotype [1, 7]. The 
same mutation occurs in hydatidiform mole, a disease which 
predisposes to choriocarcinoma [16].
Researchers have suggested a relationship between 
A6047G and T5999C mutations occuring in glioblastoma 
multiforme and oxidative stress in cancerous cells. They 
suspect there is a correlation between the transition and 
both respiratory chain failure and an increased concentra-
tion of reactive oxygen species [13, 23–26]. Investigators of 
mtDNA variants in pancreatic cancer have inferred a similar 
conclusion [14].
In the course of study on somatic mutations in human thy-
roid cancer, where 68 patients were enrolled, MT-CO1 and 
MT-CO3 gene mutations were detected in 9 patients. The 
G9477A mutation occured in tumoral and adjacent healthy 
tissue samples from 3 patients. Scientists demonstrated 
a prevalence of variants of genes encoding complex IV in 
malignant tumors compared with benign neoplasms [17]. The 
G9477A mutation, also described in ovarian cancer, increases 
the risk of its incidence by 1.27 times [18]. Another T6152C 
mutation was first described in head and neck squamous cell 
carcinomas. Researchers focused mainly on the analysis of 
D-loop vatiants, but did not imply any statistically significant 
relationship between detected alterations and head and neck 
cancers as the tested variants were too rare [15]. 
The variants of MT-CO1 and MT-CO3 described in this 
study for the first time are also transitions. One of them, 
namely A6052G, introduces serine instead of asparagine 
into the 50th locus of COX1 subunit. The sequence where the 
amino acid change occurred is not evolutionarily preserved. 
Given the low evolutionary diversity of the studied sequence 
it seems safe to assume that amino acid substitution does 
not affect polypeptide structure or function [19]. The two 
remaining variants detected in this study do not trigger any 
amino acid change in the protein product.
Due to the limited reports on MT-CO1 and MT-CO3 gene 
mutations in endometrial cancer, selected mutations and 
variants detected in endometrial cancer patients and the 
study group during MT-CO gene fragments testing were 
subject to further analysis.
It was a rather difficult task since compared with the 
variants in hypervariable D-loop region these mutations 
occur only in a small portion of the studied neoplasms. Pet-
ros et al. [1] studied mutations in MT-CO1 occuring in only 
11–12% of the population with prostate cancer and in < 2% 
of the control group. Among the 17 patients diagnosed with 
glioblastoma multiforme only one carried an MT-CO1 gene 
mutation, the remaining alterations were mostly located 
in D-loop [13]. Similarly, out of 68 thyroid cancer patients 
MT-CO1 and MT-CO3 gene mutations were detected in 
9 cases [17]. Nevertheless, the influence of mtDNA muta-
tions encoding respiratory chain subunits impairs energy 
and metabolic processes in cells, and affects the function 
of tissues and thus the whole body. The importance of this 
question prompted us to study MT-CO1 and MT-CO3 gene 
mutations in endometrial cancer.
CONCLUSIONS
The analysis performed indicates none of the remain-
ing MT-CO1 mutations (A5935G, G5949A, G6081A, G6267A) 
occur in endometrial cancer.
Three new alterations detected in this study (A6052G, 
A9545G, G9575A) were described for the first time. 
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